Fate Therapeutics (FATE) Tops Q3 EPS by 2c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.40), $0.02 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $3.07 million versus the consensus estimate of $1.24 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00